Nina Kadan-Lottick MD

Associate Professor of Pediatrics (Hematology / Oncology); Medical Director, HEROS Program

Late outcomes in survivors of childhood cancer with an emphasis on neurocognitive and psychosocial outcomes; Second malignancies; Osteoporosis

Former K-12 Scholars

Cancer Center, Yale: | | Supportive Oncology Program | Cancer Prevention and Control

Pediatrics: Pediatric Hematology & Oncology

Cancer Prevention and Control

Clinical Trials

Conditions	Study Title
Leukemia and Down Syndrome	Study of Blood Samples From Newborns With Down Syndrome
Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma, Mixed Childhood Rhabdomyosarcoma, Pleomorphic Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, and Recurrent Childhood Rhabdomyosarcoma	Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma, Mixed Childhood Rhabdomyosarcoma, Pleomorphic Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, and Recurrent Childhood Rhabdomyosarcoma	Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Fungal Infection, Leukemia, and Neutropenia	Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy
Recurrent or Refractory Solid Tumors	A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors (ADVL1221)